Stocks › PCVX
Vaxcyte, Inc.
PCVX·Nasdaq·
United States·USD
$55.39
-2.97 (-5.09%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
PCVX
Vaxcyte, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
PCVXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of PCVX by members of U.S. Congress · 9 on record · 3 in the last 12 months
Whale Activity
Position changes in PCVX reported for 2026-09-30 by 391 institutional filers
- Increased128
- New59
- Held47
- Decreased102
- Closed35
- No prior filing20
| Filer | Shares | Value | Change |
|---|---|---|---|
| FMR LLC | 22.5M | $1.28B | increased |
| Janus Henderson Group Ltd. | 17.9M | $1.02B | — |
| T. Rowe Price Investment Management, Inc. | 14.3M | $813.7M | increased |
| BlackRock, Inc. | 12.2M | $693.0M | increased |
| RA CAPITAL MANAGEMENT, L.P. | 11.5M | $652.9M | held |
| WELLINGTON MANAGEMENT GROUP LLP | 7.7M | $440.1M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.6M | $373.9M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.6M | $373.8M | decreased |
| STATE STREET CORP | 5.2M | $297.7M | decreased |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.5M | $200.9M | increased |
| Deep Track Capital, LP | 3.5M | $199.9M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 3.5M | $198.9M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by PCVX insiders, by quarter · Form 4
Recent Insider Transactions
938 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Dhaliwal Harpreet S.Chief Technical Ops Officer | Sale | −9,345 | $68.16 | $637K | Nov 11, 2026 | Form 4 ↗ |
| Dhaliwal Harpreet S.Chief Technical Ops Officer | Sale | −7,135 | $67.33 | $480K | Nov 11, 2026 | Form 4 ↗ |
| Dhaliwal Harpreet S.Chief Technical Ops Officer | Sale | −520 | $68.82 | $36K | Nov 11, 2026 | Form 4 ↗ |
| Cowan ElviaSVP, Finance & CAO | Sale | −586 | $61.55 | $36K | Nov 2, 2026 | Form 4 ↗ |
| Cowan ElviaSVP, Finance & CAO | Sale | −2,414 | $60.77 | $147K | Nov 2, 2026 | Form 4 ↗ |
| Wassil JimEVP, Chief Scientific Ofc, COO | Sale | −343 | $61.57 | $21K | Nov 2, 2026 | Form 4 ↗ |
| Wassil JimEVP, Chief Scientific Ofc, COO | Sale | −1,907 | $60.78 | $116K | Nov 2, 2026 | Form 4 ↗ |
| Cowan ElviaSVP, Finance & CAO | Sale | −19.0K | $86.74 | $1.6M | Oct 5, 2026 | Form 4 ↗ |
| Wassil JimEVP, Chief Scientific Ofc, COO | Sale | −18.0K | $86.74 | $1.6M | Oct 5, 2026 | Form 4 ↗ |
| Wassil JimEVP, Chief Scientific Ofc, COO | Sale | −95 | $57.09 | $5K | Oct 1, 2026 | Form 4 ↗ |
| Wassil JimEVP, Chief Scientific Ofc, COO | Sale | −2,155 | $56.65 | $122K | Oct 1, 2026 | Form 4 ↗ |
| Wassil JimEVP, Chief Scientific Ofc, COO | Sale | −1,334 | $59.52 | $79K | Sep 9, 2026 | Form 4 ↗ |
| Cowan ElviaSVP, Finance & CAO | Tax withholding | −1,327 | $60.36 | $80K | Sep 8, 2026 | Form 4 ↗ |
| Dhaliwal Harpreet S.Chief Technical Ops Officer | Tax withholding | −7,651 | $60.36 | $462K | Sep 8, 2026 | Form 4 ↗ |
| Wassil JimEVP, Chief Scientific Ofc, COO | Tax withholding | −5,459 | $60.36 | $330K | Sep 8, 2026 | Form 4 ↗ |
| PICKERING GRANTCHIEF EXECUTIVE OFFICER · Director | Tax withholding | −17.1K | $60.36 | $1.0M | Sep 8, 2026 | Form 4 ↗ |
| GUGGENHIME ANDREWPRESIDENT AND CFO | Tax withholding | −7,155 | $60.36 | $432K | Sep 8, 2026 | Form 4 ↗ |
| Jodar LuisChief Medical Officer | Grant / award | +52.6K | $0.00 | $0 | Sep 4, 2026 | Form 4 ↗ |
| Wassil JimEVP, Chief Scientific Ofc, COO | Sale | −1,381 | $61.16 | $84K | Sep 4, 2026 | Form 4 ↗ |
| Cowan ElviaSVP, Finance & CAO | Tax withholding | −326 | $61.58 | $20K | Sep 2, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding PCVX · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 4.6M | $266.7M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Fund T. ROWE PRICE CAPITAL APPRECIATION FUND, INC. | 4.0M | $232.9M | 0.33% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 3.4M | $197.2M | 0.24% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 3.3M | $192.6M | 0.10% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund Fidelity Rutland Square Trust II | 3.1M | $191.1M | 0.07% | Aug 31, 2026 |
| Janus Henderson Forty Fund Janus Investment Fund | 2.7M | $155.6M | 0.65% | Jun 30, 2026 |
| Janus Henderson Enterprise Fund Janus Investment Fund | 2.3M | $131.9M | 0.59% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 2.2M | $127.4M | 1.19% | Jun 30, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 2.3M | $126.6M | 0.33% | Jul 31, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.9M | $111.1M | 0.24% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list PCVX's shares (CUSIP 92243G108), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Wellington Investment Advisors Holdings LLPSCHEDULE 13G · passive (13G) · 7.7M shares5.2%
Nov 16, 2026 · ↗ - Wellington Group Holdings LLPSCHEDULE 13G · passive (13G) · 7.7M shares5.2%
Nov 16, 2026 · ↗ - Wellington Management Group LLPSCHEDULE 13G · passive (13G) · 7.7M shares5.2%
Nov 16, 2026 · ↗ - T. Rowe Price Investment Management, Inc.SCHEDULE 13G/A · passive (13G) · 18.1M shares11.6%
Nov 6, 2026 · ↗ - T. Rowe Price Investment Management, Inc.SCHEDULE 13G/A · passive (13G) · 14.3M shares9.6%
Nov 6, 2026 · ↗ - JANUS HENDERSON GROUP Ltd.SCHEDULE 13G/A · passive (13G) · 18.0M shares12.1%
Aug 11, 2026 · ↗ - JANUS HENDERSON GROUP Ltd.SCHEDULE 13G/A · passive (13G) · 65.7K shares0.1%
Aug 7, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 20.8M shares14.4%
Aug 6, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 20.8M shares14.4%
Aug 6, 2026 · ↗ - RA Capital Healthcare Fund, L.P.SCHEDULE 13G/A · passive (13G) · 12.7M shares8.7%
May 15, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming vaxcyte as client
- BGR GOVERNMENT AFFAIRSVAXCYTE, INC. · 2026 Q3 · HCR$80K
Filing ↗ - DCI GROUP, L.L.C.VAXCYTE, INC. · 2026 Q3 · HCR$75K
Filing ↗ - BGR GOVERNMENT AFFAIRSVAXCYTE, INC. · 2026 Q2 · HCR$80K
Filing ↗ - DCI GROUP, L.L.C.VAXCYTE, INC. · 2026 Q2 · HCR$75K
Filing ↗ - BGR GOVERNMENT AFFAIRSVAXCYTE, INC. · 2026 Q1 · HCR$80K
Filing ↗
Government Contracts
Federal awards to Vaxcyte, Inc. · USAspending
No federal contract awards found for Vaxcyte, Inc..
U.S. Patents
Recent USPTO applications naming Vaxcyte, Inc.
No USPTO patent applications found for Vaxcyte, Inc..
Annual Financials
From PCVX's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating income | -$923.7M | -$569.5M | -$468.0M | -$232.3M | -$103.7M |
| Net income | -$766.6M | -$463.9M | -$402.3M | -$223.5M | -$100.1M |
| Diluted EPS | -$5.63 | -$3.80 | -$4.14 | -$3.44 | -$1.93 |
| Operating cash flow | -$655.6M | -$452.6M | -$296.8M | -$170.6M | -$121.4M |
| Cash and equivalents | $174.0M | $387.9M | $397.5M | $834.7M | $69.0M |
| Total assets | $3.00B | $3.51B | $1.41B | $1.01B | $324.3M |
| Total liabilities | $317.2M | $205.5M | $167.4M | $52.6M | $40.3M |
| Shareholders' equity | $2.69B | $3.31B | $1.24B | $953.6M | $284.0M |
As Vaxcyte, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 24, 2026 ↗
Stock Splits
Every split and reverse split in the price history
No stock splits in PCVX's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsNov 4, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 8.01, 9.01Material agreement · Direct financial obligation · Other eventsOct 9, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsOct 5, 2026
EDGAR ↗ - 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureSep 3, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 5, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeJul 15, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeJun 23, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 16, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 6, 2026
EDGAR ↗
About Vaxcyte, Inc.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersSAN CARLOS, CA
IncorporatedDE
SEC CIK0001649094 ↗
Former namesSutroVax, Inc.



